Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.56 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085732 | 1.00 | LTA4H (0.66) | LTA4HPTGS2ATML3MBTL1KDM4E | |
| SCHEMBL1640980 | 0.98 | LTA4H (0.68) | LTA4HPTGS2ATML3MBTL1KDM4E | |
| SCHEMBL4080457 | 0.95 | LTA4H (0.64) | LTA4HPTGS2ATML3MBTL1KDM4E | |
| SCHEMBL4090273 | 0.93 | ATM (0.68) | ATML3MBTL1KDM4EHRH3NPSR1 | |
| SCHEMBL8780108 | 0.89 | ATM (0.59) | LTA4HPTGS2ATML3MBTL1KDM4E | |
| SCHEMBL5754492 | 0.88 | LTA4H (0.56) | LTA4HPTGS2KDM4EPOLBGAA | |
| SCHEMBL227976 | 0.85 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1KDM4E | |
| SCHEMBL227425 | 0.85 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1KDM4E | |
| SCHEMBL5442329 | 0.85 | TSHR (0.66) | LTA4HKDM4EHRH3 | |
| SCHEMBL30186207 | 0.84 | HRH3 (0.81) | LTA4HHRH3MAOBBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | LTA4H 2426/4885PTGS2 1655/4885ATM 107/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | LTA4H 2448/4885PTGS2 1604/4885ATM 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.